104 lines
3.8 KiB
JSON
104 lines
3.8 KiB
JSON
{
|
|
"study": "42847922MDD3003",
|
|
"report_id": 92,
|
|
"forms": [
|
|
"Acknowledgement Reporting Form",
|
|
"Acknowledgement Upload Form",
|
|
"Adverse Event of Special Interest",
|
|
"Adverse Events/Serious Aes",
|
|
"Alcohol Test",
|
|
"Arizona Sexual Experiences Scale Summary",
|
|
"Arizona Sexual Experiences Scale-Female",
|
|
"Arizona Sexual Experiences Scale-Male",
|
|
"Change in Background Antidepressant",
|
|
"Clinical Global Impression - S (Depression)",
|
|
"Clinical Outcome Assessments Completion Status",
|
|
"Columbia-Suicide Severity Rating Scale - Baseline/Screening Version",
|
|
"Columbia-Suicide Severity Rating Scale - Since Last Visit",
|
|
"Comments",
|
|
"Concomitant Therapy / Medication",
|
|
"Date of Visit",
|
|
"Death Information",
|
|
"Demographics",
|
|
"Derivation (operational form)",
|
|
"Drug Expiry Information",
|
|
"Drug Testing",
|
|
"DSL Index Page (Must have for DSL functionality; not visible to the sites) (operational form)",
|
|
"DUMMY (operational form)",
|
|
"Educational Level",
|
|
"Enrollment",
|
|
"EQ-5D-5L",
|
|
"Evaluation of Response - Induction Phase",
|
|
"Evaluation of Response - Stabilization Phase",
|
|
"General Medical History",
|
|
"Inclusion/Exclusion Criteria",
|
|
"Insomnia Severity Index",
|
|
"Insomnia Severity Index (Clinician Version)",
|
|
"Integrated Medication Kit Accountability Information Double Blind Maintenance",
|
|
"Integrated Medication Kit Accountability Information Double Blind Part 1",
|
|
"Integrated Medication Kit Accountability Information Open Label Part 2",
|
|
"Interim Investigator Signature",
|
|
"IRT Stratification",
|
|
"Local Chemistry (Unscheduled)",
|
|
"Local Hematology (Unscheduled)",
|
|
"Local Labs for Background Antidepressant Compliance",
|
|
"Menstrual Cycle Tracking",
|
|
"Menstrual Cycle Tracking Log",
|
|
"MGH ATRQ, Geriatric, Section I and II",
|
|
"MGH ATRQ, Non-Geriatric, Section I and II",
|
|
"MGH-ATRQ - Summary",
|
|
"MGH-ATRQ - Therapy Questions",
|
|
"Mini-Mental State Examination",
|
|
"Neurologic Examination",
|
|
"Patient Global Impression of Change - Depression/Insomnia",
|
|
"Patient Global Impression of Severity - Insomnia",
|
|
"Patient Health Questionnaire - 9 Item",
|
|
"Perceived Treatment Group Assignment",
|
|
"Periodic Investigator's EDC Review Acknowledgement",
|
|
"Physical Examination",
|
|
"Physician Withdrawal Checklist (PWC)",
|
|
"Pregnancy Test",
|
|
"Preplanned Surgeries/Procedures",
|
|
"Procedures",
|
|
"PROMIS - Sleep Disturbance",
|
|
"Protocol Amendment Implementation (Operational Form)",
|
|
"Psychiatric History for Major Depressive Disorder",
|
|
"Psychotherapy",
|
|
"Psychotherapy v2.0",
|
|
"Randomization",
|
|
"Relapse - MAJOR DEPRESSIVE DISORDER",
|
|
"Relapse Criteria",
|
|
"Relapse Criteria Unscheduled",
|
|
"Relevant Additional Drug Therapies",
|
|
"Relevant information Selection",
|
|
"Relevant Local Laboratory",
|
|
"Relevant Local Laboratory Data",
|
|
"Relevant Medical History",
|
|
"Relevant Preplanned Surgeries/Procedures",
|
|
"Relevant Procedures",
|
|
"Relevant Study Medication",
|
|
"Relevant Tests",
|
|
"Safety Report Form",
|
|
"SCID-CT",
|
|
"SCID-CT Insomnia Disorder Supplemental",
|
|
"Sheehan Disability Scale",
|
|
"SIGH-D-17",
|
|
"Site Independent Qualification Assessment",
|
|
"Site/Invest Identification",
|
|
"Structured Interview Guide for the Montgomery-Asberg Depression Rating Scale",
|
|
"Study Drug Administration Double Blind Maintenance",
|
|
"Study Drug Administration Double Blind Part 1",
|
|
"Study Drug Administration Open Label Part 2 - Induction",
|
|
"Study Drug Administration Open Label Part 2 - Stabilization",
|
|
"Subject",
|
|
"Subject Site Switch",
|
|
"Treatment Disposition",
|
|
"Treatment Unblinding",
|
|
"Trial Disposition Completion/ Discontinuation",
|
|
"Unscheduled Assessments",
|
|
"Unsuccessful Contact Attempts",
|
|
"Vital Signs",
|
|
"Vital Signs (Unscheduled)"
|
|
]
|
|
}
|